Calmangafodipir

Drug Profile

Calmangafodipir

Alternative Names: Aladote; PledOx; PP 100 01A; PP-095; PP-100-01

Latest Information Update: 22 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator PledPharma
  • Class Acetates; Chemoprotectants; Ethylenediamines; Pyridines; Small molecules
  • Mechanism of Action Antioxidants; Iron chelating agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Chemotherapy-induced damage
  • Phase I Liver failure

Most Recent Events

  • 08 Jun 2017 Phase-I clinical trials in Liver failure (Adjunctive treatment, In Adolescents, In Adults, Prevention) in United Kingdom (IV) (NCT03177395)
  • 09 Mar 2017 Phase-IIb development is ongoing in Germany, Georgia and Serbia
  • 20 Oct 2016 PledPharma announces intention to submit NDA and MAA to the US FDA and EMA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top